Living skin bacteria instead of antibiotics – active anti-acne skincare Sencyr launches

Beerse, Belgium, March 3, 2022:

Today's launch of Sencyr marks the first-time patients suffering from acne-prone skin have access to a cosmetic system utilising living skin bacteria to bring their own skin flora back into balance. This probiotic active skin care provides a safe and effective alternative to antibiotics and other antiacne treatments. Based on the skin’s own Cutibacterium, the probiotic modulates the skin microbiome, avoiding recurring acne cycles. The Sencyr probiotic system has been tested in extensive clinical studies and promotes the skin’s self-healing abilities. From the start, users are accompanied individually by mentors from the manufacturer S-Biomedic.

“I used to suffer from acne-prone skin myself and have been looking forward to today for a long time.” Veronika Oudova, CEO and co-founder of S-Biomedic adds. “Having an all-natural way to use live skin bacteria for long-term balance in the skin microbiome with Sencyr is great news for anyone who is as tired of constant flare-ups and heavy drug treatments, as I was back then."

Dr Bernhard Paetzold, Chief Scientific Officer and Co-Founder of S-Biomedic: “It has been shown that many supposed probiotic products on the cosmetics market do not contain any living bacteria whatsoever, or they use strains that are foreign to the skin, such as, for example, from the gut. We are the first to harness the positive effects of live skin strains and, after years of development, are proud to now offer the first clinically tested product on this basis.”

The skin probiotics in Sencyr are activated only shortly before application and are therefore applied live to the skin. Unlike non-skin bacteria, these bacteria have evolved with our human skin over thousands of years, effectively stimulating it to produce beneficial long-term compounds that help reduce breakouts and redness.

The Sencyr system is actively marketed in Germany and sold via the web shop of the manufacturer SBiomedic (Sencyr | LiveSkin Probiotics™). Founded in 2014, the start-up cooperates with well-known partners that include Beiersdorf and DSM and operates its research center in the JLABS incubator (Johnson & Johnson) in Beerse (Belgium). S-Biomedic has also secured funding for its research from the EU Horizon 2020 program.

About S-Biomedic

S-Biomedic is a Belgium-based life science company which has pioneered the effective use of living skin bacteria in cosmetics. S-Biomedic is world leader in research on the interactions between the skin and skin microbiome and in development of skin probiotics used both in cosmetics and skin treatments. Founded in 2014, the start-up is backed by well-known investors such as DSM and Beiersdorf. In addition, S-Biomedic secured funding by the renowned European Innovation Council (EIC) and the Flanders Innovation & Entrepreneurship fund (VLAIO). Located in the JLABS incubator (Johnson & Johnson), S-Biomedic operates its research center in Beerse (Belgium). For more information, visit www.sbiomedic.com.

Download the press release below.